Urgent

Systemic sclerosis (scleroderma, SSc) — overview & organ-based management (limited/diffuse cutaneous; distinct from renal crisis entry)

Systemic sclerosis · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Multisystem autoimmune connective tissue disease characterised by vasculopathy, immune activation and progressive fibrosis of skin and internal organs. Two main subsets: limited cutaneous SSc (skin distal to elbows/knees + face; CREST — Calcinosis, Raynaud, oEsophageal dysmotility, Sclerodactyly, Telangiectasia; anticentromere antibody; late pulmonary hypertension) and diffuse cutaneous SSc (proximal skin involvement; anti-Scl-70/RNA polymerase III; early ILD and renal crisis risk). Leading causes of death are pulmonary (ILD and pulmonary arterial hypertension). Management is organ-specific — there is no single disease-modifying cure. (Scleroderma renal crisis has its own dedicated entry.)

Red flags

  • New hypertension + rising creatinine +/- headache/visual change — SCLERODERMA RENAL CRISIS (start ACE inhibitor now, do not delay)
  • Rapidly progressive breathlessness/hypoxia — ILD progression or PAH
  • Syncope/chest pain/right heart failure signs — pulmonary arterial hypertension
  • Black/necrotic fingertip, critical digital ischaemia — needs iloprost/vasodilators, risk of gangrene
  • High-dose corticosteroid exposure in diffuse SSc — precipitates renal crisis

Assessment

Differential diagnosis

  • Primary Raynaud phenomenon (no organ involvement, normal nailfold capillaries, negative serology)
  • Mixed connective tissue disease / overlap (anti-U1-RNP positive)
  • Eosinophilic fasciitis (spares hands/face, peau d'orange, eosinophilia, Raynaud absent)
  • Scleromyxoedema, nephrogenic systemic fibrosis, scleroedema (diabetes)
  • Chronic GVHD; morphoea (localised scleroderma, no systemic/Raynaud)

Investigations

  • ANA + SSc-specific antibodies: anticentromere (limited), anti-Scl-70/topoisomerase (diffuse+ILD), anti-RNA polymerase III (diffuse+renal crisis/malignancy link)
  • Nailfold capillaroscopy (dilated loops, dropout = SSc pattern)
  • High-resolution CT chest + pulmonary function tests (FVC, DLCO) for ILD screen
  • Transthoracic echocardiography annually (estimate PASP) + NT-proBNP — screen for pulmonary arterial hypertension; right heart catheter to confirm
  • BP + U&E monitoring (renal crisis surveillance, especially early diffuse/anti-RNA pol III)
  • ECG/Holter (conduction disease, myocardial involvement); barium swallow/manometry if dysphagia
  • FBC, blood film (microangiopathic haemolysis in renal crisis)

Management

  • Classify subset (limited vs diffuse) and define dominant organ involvement — this drives therapy
  • Raynaud/digital ischaemia: cold avoidance, calcium-channel blocker first-line; PDE5 inhibitor and/or IV iloprost for digital ulcers; bosentan to prevent new ulcers
  • Skin fibrosis (progressive diffuse): methotrexate, mycophenolate mofetil, and/or rituximab; tocilizumab an option
  • ILD: mycophenolate mofetil or cyclophosphamide; nintedanib (antifibrotic) alone or with MMF; tocilizumab/rituximab in selected; consider lung transplant referral
  • Pulmonary arterial hypertension: refer PH centre — combination PDE5 inhibitor + endothelin receptor antagonist first-line; IV prostacyclin (epoprostenol) for advanced
  • GI: PPI for reflux/oesophagitis, prokinetics for dysmotility, rotating antibiotics for small-bowel bacterial overgrowth; nutrition support
  • BLOOD PRESSURE VIGILANCE: new hypertension + AKI = scleroderma renal crisis — start ACE inhibitor immediately (see renal crisis entry); AVOID high-dose steroids (>15 mg/day prednisolone) which precipitate it
  • Supportive: avoid cold/beta-blockers, treat calcinosis, physiotherapy, vaccination, severe refractory diffuse disease may be considered for autologous stem-cell transplant

Drugs & doses

Nifedipine MR 10-20 mg ORALLY twice daily (or amlodipine 5-10 mg daily) — first-line Raynaud [verify local dose]
Sildenafil 20 mg ORALLY three times daily (or tadalafil) for severe Raynaud/digital ulcers/PAH [verify local]
Iloprost IV infusion 0.5-2 ng/kg/min over ~6 h daily for 3-5 days for critical digital ischaemia/severe Raynaud [verify local dose]
Bosentan 62.5 mg ORALLY twice daily, up-titrate to 125 mg twice daily — reduces new digital ulcers; also PAH (LFT monitoring, teratogenic) [verify local]
Mycophenolate mofetil 1-1.5 g ORALLY twice daily for skin fibrosis and ILD [verify local dose]
Cyclophosphamide IV (e.g. 500-750 mg/m2 monthly) for severe/progressive ILD — specialist [verify local dose]
Nintedanib 150 mg ORALLY twice daily (antifibrotic) for SSc-ILD progression [verify local]
Rituximab or tocilizumab for refractory skin/lung disease — specialist [verify local]
PPI e.g. omeprazole 20-40 mg ORALLY daily (often high-dose/twice daily) for reflux oesophagitis
ACE inhibitor e.g. captopril 6.25-12.5 mg then up-titrate for scleroderma renal crisis — start immediately, do NOT stop even as creatinine rises [verify local dose]

Disposition

Specialist rheumatology + organ MDT (respiratory/PH centre, nephrology). Admit for renal crisis, critical digital ischaemia, progressive ILD/PAH or new severe organ involvement. Scleroderma renal crisis = see dedicated entry.

Complications & pitfalls

  • Interstitial lung disease and pulmonary arterial hypertension (leading causes of death)
  • Scleroderma renal crisis
  • Digital ulcers, gangrene, autoamputation; calcinosis
  • GI: reflux, dysmotility, bacterial overgrowth, gastric antral vascular ectasia ('watermelon stomach'), malnutrition
  • Myocardial fibrosis, arrhythmia, conduction block; secondary Sjogren

Exam pearls

  • AVOID glucocorticoid doses >15 mg/day prednisolone in SSc — a major precipitant of scleroderma renal crisis (worst in diffuse / anti-RNA polymerase III).
  • EULAR 2023 (updated) added mycophenolate, nintedanib, rituximab and tocilizumab as organ-directed options for skin/lung.
  • Anti-RNA polymerase III = highest renal crisis + malignancy association; anti-Scl-70 = ILD; anticentromere = limited disease/late PAH.
  • Screen every SSc patient annually with echo + PFTs for PAH and ILD — presymptomatic detection improves outcome.
  • ACE inhibitor is life-saving in renal crisis and must be continued despite rising creatinine — the opposite of usual AKI management.
  • Nailfold capillaroscopy + SSc antibodies distinguish early SSc from primary Raynaud.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.